Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Lower Limb Spasticity. Issue 2 (January 2016)

• Record Type: Journal Article
• Authors: Dashtipour, Khashayar; Chen, Jack J.; Walker, Heather W.; Lee, Michael Y.
• Editors: Onofrj., Marco
• Is Part Of: Medicine. Volume 95:Issue 2(2016)
• Page Start: e2468
• Publication Date: 2016-01
• Subjects: Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000002468
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: To elucidate clinical trial efficacy, safety, and dosing practices of AbobotulinumtoxinA (ABO) treatment in adult patients with lower limb spasticity. A systematic literature review was performed to identify randomized controlled trials of ABO in the treatment of adult lower limb spasticity. Of the 295 records identified, 6 primary publications evaluated ABO for the management of lower limb spasticity of various etiologies and were evaluated. Total ABO doses ranged between 500 and 2000 U for lower limb spasticity, depending on the muscles injected. All studies in lower limb spasticity showed statistically significant reduction in muscle tone based on Modified Ashworth Scale of ABO versus placebo. Significant effects on active movement and pain were demonstrated albeit less consistently. ABO was generally well tolerated across the individual studies; most adverse events reported were considered unrelated to treatment. Treatment-related adverse events included but not limited to fatigue, local pain at injection site, hypertonia, dry mouth, weakness of the noninjected muscle, abnormal gait, and urinary tract infection. These data from 6 randomized clinical studies provide the beginnings of an evidence base for the use of ABO to reduce lower limb spasticity. Ongoing studies in this area will add to this evidence base.